| HOME >> BIOLOGY >> TECHNOLOGY |
-------------------------------------------------------------------------
Deficit, end of period $(127,817) $(111,151)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Basic and diluted loss per common share $ (0.03) $ (0.03)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Weighted avg. number of common shares
outstanding (000's) 94,464 74,229
-------------------------------------------------------------------------
-------------------------------------------------------------------------
STATEMENTS OF CASH FLOWS Three months ended
Unaudited - In Thousands of Canadian dollars July 31,
2007 2006
----------------------
Loss for the period $ (3,100) $ (2,486)
Items not affecting cash:
Amortization 137 226
Stock-based compensation 133 147
Accretion of convertible royalty
participation units 421 300
Changes in non-cash working capital items
relating to operating activities (13) (1,295)
-------------------------------------------------------------------------
Cash used in operating activities $ (2,422) $ (3,108)
-------------------------------------------------------------------------
Issuance of common shares, net of issue costs
'/>"/>
| SOURCE MIGENIX Inc. Copyright©2007 PR Newswire. All rights reserved |